AP393A - Substituted pipecolinic and acid derivatives as HIV protease inhibitors. - Google Patents

Substituted pipecolinic and acid derivatives as HIV protease inhibitors. Download PDF

Info

Publication number
AP393A
AP393A APAP/P/1993/000495A AP9300495A AP393A AP 393 A AP393 A AP 393A AP 9300495 A AP9300495 A AP 9300495A AP 393 A AP393 A AP 393A
Authority
AP
ARIPO
Prior art keywords
butyl
tert
hydroxy
carboxamide
amino
Prior art date
Application number
APAP/P/1993/000495A
Other languages
English (en)
Other versions
AP9300495A0 (en
Inventor
Paul Cates Anderson
Francois Soucy
Christianneof YOAKIM
Pierre Lavalle
Peirre Louise Beaulieu
Original Assignee
Boehringer Ingelheim Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Canada Ltd filed Critical Boehringer Ingelheim Canada Ltd
Publication of AP9300495A0 publication Critical patent/AP9300495A0/xx
Application granted granted Critical
Publication of AP393A publication Critical patent/AP393A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1993/000495A 1992-03-13 1993-03-10 Substituted pipecolinic and acid derivatives as HIV protease inhibitors. AP393A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85071692A 1992-03-13 1992-03-13

Publications (2)

Publication Number Publication Date
AP9300495A0 AP9300495A0 (en) 1993-04-30
AP393A true AP393A (en) 1995-08-07

Family

ID=25308925

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1993/000495A AP393A (en) 1992-03-13 1993-03-10 Substituted pipecolinic and acid derivatives as HIV protease inhibitors.

Country Status (25)

Country Link
US (1) US5807870A (pl)
EP (1) EP0560268B1 (pl)
JP (1) JP3258422B2 (pl)
KR (1) KR950700253A (pl)
AP (1) AP393A (pl)
AT (1) ATE116640T1 (pl)
AU (1) AU670582B2 (pl)
CA (1) CA2131185C (pl)
CZ (1) CZ285589B6 (pl)
DE (1) DE69300043T2 (pl)
DK (1) DK0560268T3 (pl)
ES (1) ES2066623T3 (pl)
FI (1) FI944217A7 (pl)
GR (1) GR3015622T3 (pl)
HU (2) HUT70617A (pl)
IL (1) IL105035A (pl)
NO (1) NO302570B1 (pl)
NZ (1) NZ251267A (pl)
OA (1) OA10092A (pl)
PH (1) PH30734A (pl)
PL (1) PL176362B1 (pl)
RU (1) RU2140911C1 (pl)
SK (1) SK280161B6 (pl)
WO (1) WO1993018003A1 (pl)
ZA (1) ZA931776B (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07504654A (ja) 1992-03-11 1995-05-25 ナルヘックス　リミテッド オキソ及びヒドロキシ置換炭化水素のアミン誘導体
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
MXPA93002392A (es) 1992-03-11 2005-02-04 Narhex Ltd Derivados amino de hidrocarburos-oxo e hidroxi-substituidos.
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0610745A3 (en) * 1993-02-09 1994-09-28 Miles Inc Novel aminomethylene derivatives as immunosuppressants.
IL110898A0 (en) * 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2137406C (en) * 1994-12-06 2005-09-13 Pierre Louis Beaulieu Process for key intermediates for hiv protease inhibitors
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6251906B1 (en) 1998-05-15 2001-06-26 Abbott Laboratories Retroviral protease inhibiting compounds
TR201809435T4 (tr) 2000-01-19 2018-07-23 Abbvie Inc Geliştirilmiş farmasötik formülasyonlar.
DE60124080T2 (de) * 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
JP2004502664A (ja) * 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病処置用化合物
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
BR0210721A (pt) * 2001-06-27 2004-07-20 Elan Pharm Inc Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
US7662852B2 (en) 2003-05-22 2010-02-16 Lead Chemical Co., Ltd. Compounds and preparations having antiviral effect
EP2301919A1 (en) * 2004-06-10 2011-03-30 Board of Trustees of Michigan State University Synthesis of caprolactam from lysine
EP1910317B1 (en) * 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
CN101541746B (zh) * 2007-02-20 2013-01-02 密执安州立大学董事会 用于生产己内酰胺的催化脱氨基
CN101631568B (zh) 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
US9095620B2 (en) 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
WO2010011967A1 (en) * 2008-07-24 2010-01-28 Draths Corporation Methods of making cyclic amide monomers, and related derivatives and methods
JP2012530069A (ja) 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346847A2 (en) * 1988-06-13 1989-12-20 F. Hoffmann-La Roche Ag Amino acid derivatives
EP0432695A2 (en) * 1989-12-11 1991-06-19 F. Hoffmann-La Roche Ag Amino acid derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264106B1 (en) * 1986-10-14 1994-03-16 Banyu Pharmaceutical Co., Ltd. 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use
JPH07106992B2 (ja) * 1988-06-13 1995-11-15 三菱石油株式会社 ２，６―ジメチルナフタレンの分離方法
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
CA2060844A1 (en) * 1991-02-08 1992-08-09 Yabe Yuichiro Beta-amino-alpha-hydroxycarboxylic acids and their use
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
ZA931777B (en) * 1992-03-13 1993-09-23 Bio Mega Boehringer Ingelheim Substituted pyrrolidine derivatives as HIV protease inhibitors.
IL110255A (en) * 1993-07-16 1998-12-06 Merck & Co Inc Formation and resolution of 2-tert-butylcarboxamido-piperazine
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
GB2292146A (en) * 1994-08-11 1996-02-14 Merck & Co Inc HIV protease inhibitors useful for the treatment of AIDS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346847A2 (en) * 1988-06-13 1989-12-20 F. Hoffmann-La Roche Ag Amino acid derivatives
EP0432695A2 (en) * 1989-12-11 1991-06-19 F. Hoffmann-La Roche Ag Amino acid derivatives

Also Published As

Publication number Publication date
JPH0673004A (ja) 1994-03-15
CA2131185C (en) 1997-05-27
SK109094A3 (en) 1995-05-10
GR3015622T3 (en) 1995-06-30
US5807870A (en) 1998-09-15
RU94040841A (ru) 1996-07-20
RU2140911C1 (ru) 1999-11-10
WO1993018003A1 (en) 1993-09-16
EP0560268A1 (en) 1993-09-15
AU670582B2 (en) 1996-07-25
FI944217A0 (fi) 1994-09-13
OA10092A (en) 1996-12-18
NO943383D0 (no) 1994-09-12
HUT70617A (en) 1995-10-30
EP0560268B1 (en) 1995-01-04
IL105035A (en) 1997-07-13
FI944217L (fi) 1994-09-13
ATE116640T1 (de) 1995-01-15
AP9300495A0 (en) 1993-04-30
NO302570B1 (no) 1998-03-23
CZ285589B6 (cs) 1999-09-15
HU9402613D0 (en) 1994-11-28
CA2131185A1 (en) 1993-09-16
PL176362B1 (pl) 1999-05-31
AU3880893A (en) 1993-10-05
NZ251267A (en) 1996-09-25
IL105035A0 (en) 1993-07-08
JP3258422B2 (ja) 2002-02-18
KR950700253A (ko) 1995-01-16
ES2066623T3 (es) 1995-03-01
CZ223294A3 (en) 1995-11-15
SK280161B6 (sk) 1999-09-10
ZA931776B (en) 1993-09-24
FI944217A7 (fi) 1994-09-13
DE69300043D1 (de) 1995-02-16
NO943383L (no) 1994-09-12
PH30734A (en) 1997-10-17
DE69300043T2 (de) 1995-05-24
DK0560268T3 (da) 1995-06-12
HU211854A9 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
AP393A (en) Substituted pipecolinic and acid derivatives as HIV protease inhibitors.
DE69319351T2 (de) Hydroxyethylaminosulfamidsäure-derivate verwendbar als inhibitoren retroviraler proteasen
US5552405A (en) Substituted pyrrolidine derivatives as HIV protease inhibitors
US5545640A (en) Protease inhibiting succinic acid derivatives
US5614533A (en) Substituted pipecolinic acid derivatives as HIV protease inhibitors
DE69326077T2 (de) Sulfonylalkanoylaminohydroxyethylaminosulfaminsäuren verwendbar als inhibitoren retroviraler proteasen
HUP9803040A2 (hu) Tiazolszármazékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
CA2036397C (en) Hiv protease inhibitors containing derived amino acid units
Budt et al. HIV protease inhibitor HOE/BAY 793, structure-activity relationships in a series of C2-symmetric diols
EP0687675A2 (en) Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof
CA2217030C (en) Protease inhibiting succinic acid derivatives
US5696134A (en) Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof
CN1096292A (zh) 取代的吡咯烷衍生物用作hiv蛋白抑制剂
CN1096293A (zh) 用作hiv蛋白酶抑制剂的取代2-哌啶酸衍生物